Protocol II
News and Video Search Results
News coverage
-
Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
GlobeNewswire
-
Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
GlobeNewswire
-
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
-
Verde Announces Q1 2024 Results
GlobeNewswire
0 shares
1 views
You might like
Protocol II media coverage
Tocvan Drills Biggest Intersect Outside of Main Zone to Date Returns 56.4 meters of 1.0 g/t Gold Near Surface, Including 9.2 meters of 5.3 g/t Gold
Accesswire
*Highlights:*
*First Results for 2024 Drill Program Return Best Ever Intersect from 4-T Trend, 400 meters East of Main..
-
Faraday Copper Intersects 0.41% Copper Over 42.02 Metres Expanding Near-Surface Mineralization at Area 51 within the Copper Creek Project
Accesswire
-
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
-
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
GlobeNewswire
-
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
GlobeNewswire
Advertisement
More coverage
GAS CHAMBER 2.0? TRINARY BIOWEAPON OF VACCINE+HCQ+REMDESIVIR = ZYKLON B #DIEDSUDDENLY (4THREICH.COM)
Rumble
BAAL Gates: "The Final Solution" = Covid-19 is the new Zyklon B!..
-
AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
GlobeNewswire
-
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire